Abstract: Objective:To evaluate the efficacy and safety of sequential platinum regimen in young patients with diffuse large B-cell lym -phoma (DLBCL). Methods:Newly diagnosed young patients with DLBCL, who were hospitalized from January2005to June 2012in the Affiliated Cancer Hospital of Zhengzhou University, were selected according to the requirements. The patients were divided into stan-dard and sequential platinum regimen groups. The remission rates were compared using χ2 test, whereas the five-year survival rates between the two groups were compared using the Kaplan –Meier method. Multivariate survival analysis was performed using the Cox proportional regression. Subgroup analysis was conducted to select candidate patients for the sequential platinum regimen. Results:A total of 331 patients were enrolled in the study, in which129 were provided with sequential platinum regimen and 202 were provided with the standard regimen. Sequential regimen yielded higher rates of complete remission ( 80% vs . 63%,P=0. 001 ), five-year progres -sion-free survival (PFS; 60% vs . 50%, P=0. 014 ), and overall survival (OS; 70% vs . 58%, P=0. 016 ) than the standard regimen. Multivariate analysis revealed that sequential regimen was an independent prognostic factor for PFS (hazard ratio HR=0. 635 , P=0. 012 ) and OS ( HR=0. 625 , P=0. 021 ). Subgroup analysis showed that patients with good prognosis and patients who did not receive rituximab benefited more from the sequential platinum regimen. Sequential platinum regimen did not increase the occurrence of adverse effects com-pared with the standard regimen. Conclusion: Sequential platinum regimen is a safe treatment that can improve the survival of young patients with DLBCL. Patients with good prognosis and patients who did not receive rituximab can benefit more from the treatment with sequential platinum regimen.